基于黄芩汤YIV906（PHY906）思考中医药抗肿瘤现代化研究策略
Strategy of modernization of anti-tumor research of traditional Chinese medicine based on Huangqin Decoction YIV 906 (PHY906)
- 北京中医药 2022年41卷第12期 页码：1393-1397
- 作者机构：
1.北京中医药大学东直门医院血液肿瘤科，北京 100700
- 作者简介：
许晶，女，28岁，博士研究生，医师。研究方向：中西医结合防治恶性肿瘤。
侯丽，E-mail：houli1203@126.com
- 基金信息：国家自然科学基金面上项目(81573959;82074240;82172760);国家级外专项目(G2021110001L);首都卫生发展科研专项(2020-2-4193)
DOI：10.16025/j.1674-1307.2022.12.016
中图分类号：
扫 描 看 全 文
许晶，王婧，吴洁雅，等.基于黄芩汤YIV906（PHY906）思考中医药抗肿瘤现代化研究策略［J］.北京中医药，2022，41（12）：1393-1397.
XU Jing,WANG Jing,WU Jie-ya,et al.Strategy of modernization of anti-tumor research of traditional Chinese medicine based on Huangqin Decoction YIV 906 (PHY906)[J]. Beijing Journal of Traditional Chinese Medicine,2022,41(12):1393-1397.
许晶，王婧，吴洁雅，等.基于黄芩汤YIV906（PHY906）思考中医药抗肿瘤现代化研究策略［J］.北京中医药，2022，41（12）：1393-1397. DOI： 10.16025/j.1674-1307.2022.12.016.
XU Jing,WANG Jing,WU Jie-ya,et al.Strategy of modernization of anti-tumor research of traditional Chinese medicine based on Huangqin Decoction YIV 906 (PHY906)[J]. Beijing Journal of Traditional Chinese Medicine,2022,41(12):1393-1397. DOI： 10.16025/j.1674-1307.2022.12.016.
摘要
中医药抗肿瘤现代化是中医肿瘤学发展的必然趋势。YIV906源于中医传统处方黄芩汤，采用标准化生产工艺，保证了黄芩汤质量的一致性，起初被命名为PHY906，后更名为YIV906。研究探寻YIV906处方渊源，明确YIV906与传统黄芩汤的联系及不同之处，以YIV906的研究思路为导向，从基础研究、临床研究的设计和评价体系，以及中药质量一致性等方面，探讨中医药抗肿瘤现代化研究策略，为今后中医药现代化抗肿瘤研究提供思路。
Abstract
关键词
YIV906黄芩汤中医药现代化肿瘤
Keywords
references
郑永齐. 黄芩汤治疗肝癌的现代化研究实践[J]. 中西医结合肝病杂志,2019,29(2):103-105,111.
陈敏妃, 李华峰, 许志良. 黄芩汤病机初探[J]. 浙江中医药大学学报,2016,40(12):926-927,931.
KUMMAR S, COPUR MS, ROSE M, et al. A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer[J]. Clin Colorectal Cancer,2011,10(2):85-96.
欧燕, 戴艺, 蒲俊勇. 黄芩汤在消化系统肿瘤化疗患者中的应用进展[J]. 医学综述,2021,27(9):1802-1806.
ROCKWELL S, GROVE TA, LIU Y, et al. Preclinical studies of the Chinese Herbal Medicine formulation PHY906 (KD018) as a potential adjunct to radiation therapy[J]. Int J Radiat Biol,2013,89(1):16-25.
YE M, LIU SH, JIANG Z, et al. Liquid chromatography/mass spectrometry analysis of PHY906, a Chinese medicine formulation for cancer therapy[J]. Rapid Commun Mass Spectrom,2007,21(22):3593-3607.
TILTON R, PAIVA AA, GUAN JQ, et al. A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqin Tang (HQT) and PHY906[J]. Chin Med,2010,5:30.
LAM W, REN Y, GUAN F, et al. Mechanism based quality control (MBQC) of herbal products: A case study YIV-906 (PHY906)[J]. Front Pharmacol,2018,9:1324.
FARRELL MP, KUMMAR S. Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer[J]. Clin Colorectal Cancer,2003,2(4):253-256.
SAIF MW, LANSIGAN F, RUTA S, et al. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies[J]. Phytomedicine,2010,17(3-4):161-169.
SAIF MW, LI J, LAMB L, et al. First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer[J]. Cancer Chemother Pharmacol,2014,73(2):373-380.
YEN Y, SO S, ROSE M, et al. Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma[J]. Anticancer Res,2009,29(10):4083-4092.
LAM W, BUSSOM S, GUAN F, et al. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity[J]. Sci Transl Med,2010,2(45):45ra59.
WANG E, BUSSOM S, CHEN J, et al. Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment[J]. BMC Med Genomics,2011,4:38.
LAM W, JIANG Z, GUAN F, et al. PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment[J]. Sci Rep,2015,5:9384.
YANG X, LAM W, JIANG Z, et al. YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment[J]. Sci Rep,2021,11(1):13482.
赖春丽, 黄婉锋, 祝晨蔯,等. 抗肿瘤中药新药开发探讨[J]. 中药材,2003(9):677-680.
毕启瑞,李运,高敏,等.抗肿瘤中药研究进展[J].中医肿瘤学杂志,2021,3(4):1-11.
谭婉燕, 熊枝繁. 中药抗肿瘤临床应用的相关思考[J]. 山西医科大学学报,2017,48(9):966-967.
陶李蕙苹, 赖岳阳, 沈政洁,等. 中医肿瘤学现代化发展的现状及思考[J]. 世界科学技术-中医药现代化,2021,23(3):905-910.
姜菊玲, 刘瑞, 郑红刚,等. 基于中医药现代化抗肿瘤中药新药研发策略探讨和思考[J]. 中华中医药杂志,2021,36(1):50-55.
伍振峰,林瑞华,王学成,等.基于中药制药工程质量观的质量控制模式研究[J].中国中药杂志,2022,47(1):271-278.
戴跃龙, 白慧颖, 窦永起. 黄芩汤PHY906的研究进展[J]. 武警后勤学院学报(医学版),2015,24(9):754-757.
王珺, 陈信义, 赖宗浪,等. 复方浙贝颗粒辅助化疗改善难治性急性白血病患者症状的临床观察[J]. 北京中医药,2013,32(11):833-835.
HOU L, YANG S, YANG W, et al. Compound Zhebei granules combined with chemotherapy for the treatment of refractory acute leukemia: a randomized clinical trial[J]. J Tradit Chin Med,2016,36(5):606-612.
张寅.复方浙贝颗粒配方辅助化疗提高难治性急性白血病疗效的临床研究[D].北京：北京中医药大学,2007.
赖宗浪.以LSC为靶标的复方浙贝颗粒抗AML临床研究[D].北京：北京中医药大学,2014.
吕鹏, 赵欢, 石凤芹,等. 复方浙贝颗粒联合顺铂对急性淋巴细胞白血病耐药细胞株移植瘤细胞耐药相关酶表达的影响[J]. 中国中医药信息杂志,2019,26(11):52-56.
CHEN Z, ZHAI XF, SU YH, et al. Clinical observation of cinobufacini injection used to treat moderate and advanced primary liver cancer[J]. Zhong Xi Yi Jie He Xue Bao,2003,1(3):184-186.
QIN SK, LI Q, XU JM, et al. Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival[J]. Cancer Sci,2020,111(11):4218-4231.
FAN Y, LI S, DING X, et al. First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers[J]. BMC Cancer,2019,19(1):279.
WANG L, ZHOU GB, LIU P, et al.Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia[J]. Proc Natl Acad Sci USA，2008，105(12):4826-4831.
0
浏览量
0
下载量
0
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备18046208号-2
京公网安备 11010102006710号 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies